{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:45:17Z","timestamp":1789148717392,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Together with impaired mucociliary clearance, lung disease in cystic fibrosis (CF) is driven by dysregulation of innate and adaptive immunity caused by dysfunctional CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), leading to airway infection and hyperinflamma-tion. The highly effective CFTR modulator therapy (HEMT) elexacaftor\/tezacaftor\/ivacaftor (ETI) generates substantial improvements in clinical outcomes of people with CF (pwCF) by restoration of CFTR activity. Aberrant immune responses of lymphocytes due to CFTR dysfunction has been described in the past, but not the effects of CFTR restoration by HEMT on these cells. We aimed to examine the effect of ETI on the proliferative activity of antigen-specific CD154 (+) T cells against bacterial and fungal species relevant in CF and on total IgG and IgE as markers of B cell adaptive immunity.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed <jats:italic>ex vivo<\/jats:italic> analyses of Ki-67 expression in antigen-specific CD154 (+) T cells against <jats:italic>Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus fumigatus, Scedosporium apiospermum<\/jats:italic> and <jats:italic>Candida albicans<\/jats:italic> from 21 pwCF by cytometric assay based on antigen-reactive T cell enrichment (ARTE), and analysis of total serum IgE and IgG before and after initiation of ETI.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mean Ki-67 expression in antigen-specific CD154 (+) T cells against <jats:italic>P. aeruginosa, A. fumigatus, S. apiospermum<\/jats:italic> and <jats:italic>C. albicans<\/jats:italic>, but not <jats:italic>S. aureus<\/jats:italic>, mean total serum IgG and mean total serum IgE decreased significantly after initiation of ETI. No correlation was found to change in sputum microbiology of the examined pathogens. Mean BMI and FEV1 increased significantly.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> HEMT is associated with decreased antigen-specific CD154 (+) T cell proliferation activity in our cohort, independent of findings in sputum microbiology of the examined pathogens. Together with the observed clinical improvement and the decrease in total IgE and IgG, this indicates effects due to CFTR restoration on CD154 (+) T cells by ETI and a reduction of B cell activation with subsequent lower immunoglobulin synthesis under HEMT therapy. These results endorse earlier evidence of CFTR dysfunction in T and B cells leading directly to aberrant immune responses with hyperinflammation.<\/jats:p>","DOI":"10.3389\/fphar.2023.1180826","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T06:20:01Z","timestamp":1687242001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Patience N.","family":"Eschenhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Grehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen G.","family":"Mainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Scheffold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2019.01.041","article-title":"Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans","volume":"176","author":"Bacher","year":"2019","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.4049\/jimmunol.1202221","article-title":"Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire","volume":"190","author":"Bacher","year":"2013","journal-title":"J. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr. Pulmonol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11046-021-00541-5","article-title":"CF fungal disease in the age of CFTR modulators","volume":"186","author":"Bercusson","year":"2021","journal-title":"Mycopathologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcf.2022.09.007","article-title":"Advent of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis treatment: What consequences on aspergillus-related diseases? Preliminary insights","volume":"21","author":"Chesnay","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.3109\/13693786.2010.503320","article-title":"Candida species in cystic fibrosis: A road less travelled","volume":"48","author":"Chotirmall","year":"2010","journal-title":"Med. Mycol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fcimb.2020.00372","article-title":"CFTR modulators dampen aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes","volume":"10","author":"Currie","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"13502","DOI":"10.1074\/jbc.RA119.009934","article-title":"Exposure of Pseudomonas aeruginosa to bactericidal hypochlorous acid during neutrophil phagocytosis is compromised in cystic fibrosis","volume":"294","author":"Dickerhof","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/s41423-020-0499-3","article-title":"CFTR is a negative regulator of \u03b3\u03b4 T cell IFN-\u03b3 production and antitumor immunity","volume":"18","author":"Duan","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/02770903.2017.1373808","article-title":"F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis","volume":"55","author":"Gamaletsou","year":"2018","journal-title":"J. Asthma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ccm.2022.06.003","article-title":"Genetics of cystic fibrosis: Clinical implications","volume":"43","author":"Joynt","year":"2022","journal-title":"Clin. Chest Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.3390\/ijms21176379","article-title":"Airway inflammation and host responses in the era of CFTR modulators","volume":"21","author":"Keown","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12421","DOI":"10.3390\/ijms232012421","article-title":"Impact of CFTR modulators on the impaired function of phagocytes in cystic fibrosis lung disease","volume":"23","author":"Meoli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1046\/j.1365-2249.1996.d01-826.x","article-title":"Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"106","author":"Moss","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1165\/rcmb.2010-0224OC","article-title":"Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses","volume":"44","author":"Mueller","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/labinvest.3700379","article-title":"Enhanced IgE allergic response to Aspergillus fumigatus in CFTR-\/- mice","volume":"86","author":"Muller","year":"2006","journal-title":"Lab. Invest."},{"key":"B21","volume-title":"German cystic fibrosis registry - annual report","author":"N\u00e4hrlich","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s10038-020-00874-x","article-title":"Genome-wide association study of individual differences of human lymphocyte profiles using large-scale cytometry data","volume":"66","author":"Okada","year":"2021","journal-title":"J. Hum. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.1021\/bi060490t","article-title":"CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microb. Spectr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12931-019-1103-1","article-title":"CFTR regulates B cell activation and lymphoid follicle development","volume":"20","author":"Polverino","year":"2019","journal-title":"Respir. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1165\/rcmb.2011-0399RT","article-title":"Immune responses in cystic fibrosis: Are they intrinsically defective?","volume":"46","author":"Ratner","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311:AID-JCP1>3.0.CO;2-9","article-title":"The ki-67 protein: From the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell Phys."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e161593","DOI":"10.1172\/JCI161593","article-title":"Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis","volume":"133","author":"Schwarz","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/s0022-3476(84)80946-4","article-title":"Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: A 5-year longitudinal study","volume":"104","author":"Wheeler","year":"1984","journal-title":"Pediatrics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1000155","DOI":"10.1371\/journal.pbio.1000155","article-title":"CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium","volume":"7","author":"Zhang","year":"2009","journal-title":"PLoS Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2022","journal-title":"Eur. Respir. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1180826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T06:20:03Z","timestamp":1687242003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1180826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":33,"alternative-id":["10.3389\/fphar.2023.1180826"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1180826","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"article-number":"1180826"}}